Stock Scorecard
Stock Summary for IQVIA Holdings Inc (IQV) - $233.98 as of 4/26/2024 3:23:01 PM EST
Total Score
9 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for IQV
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for IQV
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for IQV
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for IQV
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for IQV
Financial Details for IQV
Company Overview |
|
---|---|
Ticker | IQV |
Company Name | IQVIA Holdings Inc |
Country | USA |
Description | IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services. |
Sector Name | TRADE & SERVICES |
Industry Name | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/2/2024 |
Stock Price History |
|
Last Day Price | 233.98 |
Last Day Price Updated | 4/26/2024 3:23:01 PM EST |
Last Day Volume | 0 |
Average Daily Volume | 825,200 |
52-Week High | 261.73 |
52-Week Low | 167.42 |
Last Price to 52 Week Low | 39.76% |
Valuation Measures |
|
Trailing PE | 32.18 |
Industry PE | 31.76 |
Sector PE | 39.76 |
5-Year Average PE | 20.39 |
Free Cash Flow Ratio | 28.46 |
Industry Free Cash Flow Ratio | 41.88 |
Sector Free Cash Flow Ratio | 87.16 |
Current Ratio Most Recent Quarter | 0.86 |
Total Cash Per Share | 8.22 |
Book Value Per Share Most Recent Quarter | 33.67 |
Price to Book Ratio | 6.98 |
Industry Price to Book Ratio | 8.15 |
Sector Price to Book Ratio | 8.79 |
Price to Sales Ratio Twelve Trailing Months | 2.85 |
Industry Price to Sales Ratio Twelve Trailing Months | 4.00 |
Sector Price to Sales Ratio Twelve Trailing Months | 1.87 |
Share Statistics |
|
Total Shares Outstanding | 182,014,000 |
Market Capitalization | 42,587,635,720 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 112.50% |
Annual Earnings Growth | 24.47% |
Reported EPS 12 Trailing Months | 7.30 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | 10.21 |
Net Income Twelve Trailing Months | 1,358,000,000 |
Net Income Past Year | 1,358,000,000 |
Net Income Prior Year | 1,091,000,000 |
Quarterly Revenue Growth YOY | 3.50% |
5-Year Revenue Growth | 7.44% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 1,496,000,000 |
Total Cash Past Year | 1,496,000,000 |
Total Cash Prior Year | 1,309,000,000 |
Net Cash Position Most Recent Quarter | -25,929,000,000 |
Net Cash Position Past Year | -25,929,000,000 |
Long Term Debt Past Year | 27,425,000,000 |
Long Term Debt Prior Year | 25,544,000,000 |
Total Debt Most Recent Quarter | 27,425,000,000 |
Equity to Debt Ratio Past Year | 0.18 |
Equity to Debt Ratio Most Recent Quarter | 0.18 |
Total Stockholder Equity Past Year | 6,112,000,000 |
Total Stockholder Equity Prior Year | 5,765,000,000 |
Total Stockholder Equity Most Recent Quarter | 6,112,000,000 |
Options |
|
Put/Call Ratio | 0.78 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -3.19 |
MACD Signal | -3.30 |
20-Day Bollinger Lower Band | 204.23 |
20-Day Bollinger Middle Band | 233.68 |
20-Day Bollinger Upper Band | 263.12 |
Beta | 1.52 |
RSI | 49.93 |
50-Day SMA | 217.81 |
200-Day SMA | 213.74 |
System |
|
Modified | 4/27/2024 3:35:12 AM EST |